Menu
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.
5403 Betsy Ross Dr
Santa Clara, California 95054
Phone: 15102794262
shockwavemedical.com
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
With continued volatility in the stock market right now, it’s no wonder investors are looking for stocks with proven track records to bolster their portfolios. While U.S. stocks opened strong on Monday after a concerning ending to the prior week, investors are still uneasy about the current state of the market. Tensions in the Middle East, concerns that the Federal Reserve may not reduce interest rates as fast as previously hoped and fears over continued inflation are still top of mind for many investors right now. While some believe the bull market isn’t coming to an end anytime soon, others are practicing a more risk-averse investing style just in case. Investors can remain cautiously optimistic about the future of the stock market while still investing in stocks that have proven themselves winners over the long term. By doing so, they can hedge their bets and diversify their portfolios. They can still see good returns. Some companies, regardless of the geopolitical or overall economic climate, have consistently done well throughout the years.
Johnson & Johnson’s (JNJ) first-quarter profit got a boost from strong sales of medical devices, the consumer healthcare company has reported. Johnson & Johnson, whose financial results are viewed as a bellwether for the American healthcare sector, announced earnings per share of $2.71 U.S. versus $2.64 U.S. that was expected among analysts. Revenue in the quarter came in at $21.38 billion U.S. compared to $21.40 billion U.S. that was forecast on Wall Street. Sales rose 2% from a year earlier. The company’s Medtech division that makes devices for surgeries, orthopedics and vision saw a rebound in sales during Q1 as demand grows for nonurgent surgeries among elderly adults. Johnson & Johnson’s medical device business generated sales of $7.82 billion U.S. in Q1, up 4% from a year ago. The company has made growing its medical device business a priority, recently announcing a $13.10 billion U.S. acquisition of heart device firm Shockwave Medical (SWAV). Johnson & Johnson bought two other heart device companies over the last two years, spending $16.60 billion U.S. to buy Abiomed and $400 million U.S. to buy privately held Laminar.
Johnson & Johnson (NYSE: JNJ ), will be reporting its first-quarter earnings on April 16. Wall Street expects $2.64 in EPS and $21.4 billion in revenues as the company reports before market hours . Johnson & Johnson stock is down about 9.54% over the past year, and has dropped 5.88% YTD. The company confronts patent cliffs that threaten tens of billions in revenue, yet it’s strengthening its cardiac business by acquiring Shockwave Medical for $12.5 billion. Johnson & Johnson''s Stelara is facing increased competition from biosimilars, yet the company is offsetting these challenges with market share gains from newer drugs like Carvykti and Spravato. Meanwhile, strategic acquisitions of Abiomed and Laminar are anticipated to bolster its MedTech segment, countering near-term headwinds. Let’s take a look at how the stock … Full story available on Benzinga.com
The dividend kings are a select group of dividend stocks made up of companies that have increased their dividends for at least 50 consecutive years. That may be a throw-away statistic. But consider everything that’s happened to the economy in the past 50 years. Being able to continually issue a dividend speaks to the blue-chip nature of these companies. They deliver rock-solid revenue and earnings with a commitment to returning capital to shareholders. Naysayers will say those dividend payments come at the expense of growth. And, it’s true that you won’t find an Nvidia (NASDAQ: NVDA ) among this group of stocks. But that’s not to say you won’t get share price appreciation and possible market-beating growth. In 2024, only 54 stocks have earned the distinction of being a dividend king. And the three dividend stocks we’ll explore have the added benefit of receiving one or more strong buy ratings from analysts. Johnson & Johnson (JNJ) Source: Raihana Asral / Shutterstock.com Founded in 1886, Johnson & Johnson (NYSE: JNJ ) stock has been a tough hold in the last year.
NEW YORK, April 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc. (NASDAQ: SWAV)''s…
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
At 11:39 a.m. ET, the Dow Jones Industrial Average surged 266.21 points, marking a 0.69 per cent increase to reach 38,863.19. Simultaneously, the S&P 500 rose by 51.35 points, reflecting a 1.00 per cent gain, and stood at 5,198.56.
